162327-73-3

Basic information

• Product Name: 5,6-Dichloro-N-methoxy-N-methylpyridine-3-carboxamide
• Synonyms: 5,6-Dichloro-N-methoxy-N-methylpyridine-3-carboxamide
• CAS NO: 162327-73-3
• Molecular Formula: C8H8Cl2N2O2
• Molecular Weight: 235.06732
• EINECS: 939-913-2
• Mol File: 162327-73-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5,6-Dichloro-N-methoxy-N-methylpyridine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-Dichloro-N-methoxy-N-methylpyridine-3-carboxamide(162327-73-3)
• EPA Substance Registry System: 5,6-Dichloro-N-methoxy-N-methylpyridine-3-carboxamide(162327-73-3)

Safety Data

• Hazardous Substances Data: 162327-73-3(Hazardous Substances Data)

Upstream product

• 54127-29-6 5,6-dichloronicotinoyl chloride 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 41667-95-2 5,6-dichloronicotinic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 71690-05-6 5,6-dichloro-pyridine-3-carbaldehyde 
• 71690-06-7 2,3-dichloro-5-(difluoromethyl)pyridine 
• 1073616-37-1 (S)-N-(4-chloro-3-trifluoromethylphenyl)-4-(3-chloro-5-(1,2-dihydroxyethyl)pyridin-2-yl)piperazine-1-carboxamide 
• 1073616-26-8 (S)-3-chloro-5-(1,2-dihydroxyethyl)-3',6'-dihydro-2'H-[2,4']bipyridinyl-1'-carboxylic acid (3-chloro-4-trifluoromethylphenyl)amide 
• 1073616-33-7 (S)-4-(3-chloro-5-(1,2-dihydroxyethyl)pyridin-2-yl)-N-(4-trifluoromethoxyphenyl)piperazine-1-carboxamide 
• 1073617-34-1 4-(3-chloro-5-(1,1-difluoro-2-hydroxyethyl)pyridin-2-yl)-N-(4-trifluoromethylphenyl)-5,6-dihydropyridine-1(2H)-carboxamide 
• 1073616-35-9 (S)-4-(3-chloro-5-(1,2-dihydroxyethyl)pyridin-2-yl)-N-(4-trifluoromethylphenyl)piperazine-1-carboxamide 
• 1073616-24-6 (S)-3-chloro-5-(1,2-dihydroxyethyl)-N-[4-(trifluoromethyl)phenyl]-3',6'-dihydro-(2,4'-bipyridine)-1'(2'H)-carboxamide 
• 1073616-38-2 4-(3-chloro-5-(1,3-dihydroxypropan-2-yl)pyridin-2-yl)-N-(4-trifluoromethylphenyl)-5,6-dihydropyridine-1(2H)-carboxamide 
• 1073616-32-6 (S)-N-(4-tert-butylphenyl)-4-(3-chloro-5-(1,2-dihydroxyethyl)pyridin-2-yl)piperazine-1-carboxamide 
• 120800-05-7 2,3-dichloro-5-acetylpyridine 
• 1450622-25-9 (2S)-4-(2-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(2,2,2-trifluoro-1-hydroxy-1-mthylethyl)-3-pyridinyl)-3-butyn-2-ol 
• 1450622-21-5 (2R)-4-(2-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)-3-pyridinyl)-3-butyn-2-ol 
• 1450622-18-0 2-(6-(4-((6-amino-3-pyridinyl)sulfonyl)phenyl)-5-(cyclopropylethynyl)-3-pyridinyl)-1,1,1-trifluoro-2-propanol 

Relevant articles and documents

BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceuticall acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising th

HETEROARYL SUBSTITUTED HETEROCYCLYL SULFONES

The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

HETEROCYCLIC TRPV1 RECEPTOR LIGANDS

The invention relates to compounds of formulae I(a)-I(d): and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formulae I(a)-I(d) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formulae I(a)-I(d) or a pharmaceutically acceptable derivative thereof.

BICYCLOHETEROARYL COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS

The invention relates to compounds of formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof.

MONOCYCLIC COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS

The invention relates to compounds of formula I and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof.

N-HYDROXYACRYLAMIDE COMPOUNDS

A compound having the following formula (I) : wherein - R1is hydrogen, optionally substituted lower alkyl, cyclo (lower) alkyl, cyclo (higher) alkyl, optionally substituted aryl, optionally substituted heterocyclyl, or aryl-fused cyclo (lower) alkyl, R2 is hydrogen or halogen, Z is CH or N, X is formula (II) R3 is lower alkyl which may be substituted with -OH or optionally substituted aryl, or lower alkanoyl, R4 is hydrogen or lower alkyl, Y is optionally substituted lower alkylene, or a salt thereof. The compound is useful as a histone deacetylase inhibitor.

TRPV1 ANTAGONISTS AND USES THEREOF

The invention relates to compounds of formula (I) and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable derivative thereof.

THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN

A compound of Formula: (I) or a pharmaceutically acceptable derivative thereof, where Ar1, Ar2, X, R3, and m are as disclosed herein. Compounds of Formulae (I)-(V) and pharmaceutically acceptable derivatives thereof; compositions comprising an effective amount of a compound of Formulae (I)-(V) or a pharmaceutically acceptable derivative thereof; and methods for treating or preventing pain, UI, an ulcer, IBD, or IBS in an animal comprising administering to an animal in need thereof an effective amount of a compound of Formulae (I)-(V) or a pharmaceutically acceptable derivative thereof are disclosed herein.

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H- benzimidazoles

The vanilloid receptor-1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2- ylpiperazin-1-yl)-1H-benzo-[d]imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant (CFA).